Clinical Trials on Neuroectodermal Tumors in Germany

Total 928 results

Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
Daiichi Sankyo, Inc.
Plexxikon

Terminated

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

V600-mutated BRAF Unresectable Melanoma | V600-mutated BRAF Metastatic Melanoma | Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

United States, Germany, France
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Melanoma

United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Mexico, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom
Fresenius Kabi

Terminated

Quality of Care of Oncological Patients With HPN (VHPE-S)

Tumors and Home Parenteral Nutrition

Germany
Medical University Innsbruck
Pfizer

Unknown

SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme (SURGE01-07)

Glioblastoma Multiforme

Austria, Germany
Genta Incorporated

Completed

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma (AGENDA)

Melanoma

United States, France, United Kingdom, Spain, Switzerland, Australia, Canada, Germany, Poland, Italy, Austria, Czech Republic
Saint John's Cancer Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Melanoma

United States, Australia, Italy, Spain, Canada, Netherlands, Germany, Finland, Israel, Sweden, Switzerland, United Kingdom
CureVac

Active, not recruiting

Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

Glioblastoma

Belgium, Germany, Netherlands
GlaxoSmithKline

Terminated

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Melanoma

United States, Australia, Spain, Taiwan, Bulgaria, Estonia, Germany, Belgium, France, Sweden, Israel, Poland, Italy, Czechia, Switzerland, Korea, Republic of, Ireland, Canada, Argentina, Netherlands, Russian Federation, Ukraine, Aus... and more
Debiopharm International SA

Active, not recruiting

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01)

Acromegaly | GEP-NET

United Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
University Hospital Tuebingen

Completed

Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery

Epilepsy | Primary Brain Tumor

Germany
Celgene
University of Arizona

Completed

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Malignant Melanoma

Canada, United States, Australia, United Kingdom, France, Italy, Spain, Germany, Netherlands
Basilea Pharmaceutica

Completed

Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma

Neoplasms

Belgium, United Kingdom, Germany, Switzerland
Novartis Pharmaceuticals

Terminated

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

In Escalation: All Patients With Solid Tumors and Lymphoma | In Expansion: Melanoma, Non-small Cell Lung Cancer

United States, Italy, Taiwan, Belgium, Spain, Germany, Japan
Lexicon Pharmaceuticals

Completed

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Carcinoid Syndrome

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Canada, Israel
Novartis Pharmaceuticals

Completed

BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.

Pancreatic Neuroendocrine Tumors (pNET)

France, Spain, Belgium, Germany, Italy, United Kingdom, Austria, Netherlands, United States
Isarna Therapeutics GmbH

Completed

Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2

Melanoma | Colorectal Neoplasms | Pancreatic Neoplasms

Germany
Pfizer

Completed

A Trial Of SU14813 In Patients With Advanced Solid Malignancies

Neoplasms | Solid Tumors

Netherlands, Germany
GlaxoSmithKline

Completed

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Melanoma

France, Italy, Germany, Netherlands, Switzerland, United Kingdom, Austria, Australia
University Hospital, Essen

Completed

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (ImmunoCobiVem)

Malignant Melanoma

Germany, France, Greece, Serbia
Bristol-Myers Squibb

Completed

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Unresectable or Metastatic Melanoma

United States, Germany, Italy, United Kingdom, Canada, Denmark, Netherlands, Spain, Belgium, France, Switzerland, Israel, Austria, Brazil
European Organisation for Research and Treatment...

Unknown

High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma

Melanoma (Skin)

France, Switzerland, Netherlands, Poland, Finland, Belgium, United Kingdom, Austria, Germany, Italy, Israel, Slovakia, Spain, Serbia, Portugal, Russian Federation, Bulgaria, Croatia, Turkey, Estonia, Sweden
Merck Sharp & Dohme LLC

Terminated

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Advanced/Metastatic Melanoma

United States, Australia, Chile, France, Germany, Israel, Italy, Korea, Republic of, Norway, South Africa, Spain
Hoffmann-La Roche

Completed

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma (coBRIM)

Malignant Melanoma

United States, Spain, Hungary, Israel, United Kingdom, Australia, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Russian Federation, Sweden, Switzerland, Canada, New Zealand, Norway
Genentech, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Melanoma

United States, Germany, Australia, Korea, Republic of, Canada, Norway
Prof. Dr. Wolfgang Wick
Essex Pharma GmbH

Completed

Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma (DIRECTOR)

Glioblastoma

Germany, Austria, Switzerland
European Organisation for Research and Treatment...
NCIC Clinical Trials Group

Unknown

Adjuvant PEG Intron in Ulcerated Melanoma

Ulcerated Melanomas

France, Denmark, Italy, Belgium, Spain, United Kingdom, Netherlands, Austria, Germany, Poland, Switzerland, Portugal
European Organisation for Research and Treatment...

Recruiting

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study (LEGATO)

First Progression of Glioblastoma

Netherlands, Austria, Germany
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Participants With Metastatic Melanoma

Malignant Melanoma

Canada, Spain, United Kingdom, Hungary, Australia, Austria, Belgium, Ecuador, Estonia, Finland, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Slovenia, Sweden, Turkey, Brazil, India, Germany, Bosnia and Herzegovina and more
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma

Glioblastoma Multiforme

Germany
University Hospital Tuebingen

Terminated

Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma

Metastatic Melanoma | Brain Metastases

Germany
Glycotope GmbH

Completed

PankoMab-GEX™: Phase 1 Dose Escalation Study

Solid Tumors

Germany, Italy, Switzerland
Novartis Pharmaceuticals

Completed

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Pancreatic Neoplasms | Neuroendocrine Tumor | Neuroendocrine Carcinoma | Islet Cell Carcinoma

United States, Canada, Spain, Argentina, Germany, Belgium, Italy, France, Sweden, Australia, Netherlands
Pfizer

Completed

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma (LOGIC-2)

Melanoma

United States, Australia, Canada, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom
University of Wuerzburg

Completed

Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy

Adrenocortical Carcinoma | Adrenal Tumor

Germany
NovoCure Ltd.

Recruiting

TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study

Glioblastoma

Germany
Bristol-Myers Squibb

Completed

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma (IMAGE)

Advanced Cutaneous Melanoma

Germany, Poland, Spain, Australia, France, Argentina, Ireland, Israel, Belgium, United States, Switzerland, United Kingdom, Greece, Austria, Canada
Celgene
ICON Clinical Research

Completed

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Melanoma | Neoplasm Metastasis

Australia, United Kingdom, Ukraine, Germany, Estonia, Latvia, Lithuania, Netherlands, South Africa
Medical Research Council
Merck Sharp & Dohme LLC; Aarhus University Hospital; NCRI Clinical Studies Groups and other collaborators

Unknown

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Glioblastoma

United States, Italy, Belgium, Germany, Poland, Russian Federation, Spain, Switzerland, Ukraine, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K)

Melanoma

Italy, Poland, United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Netherlands, Norway, Romania, Spain, Switzerland, United Kingdom, Sweden
Bayer

Completed

Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body

Solid Tumors Harboring NTRK Fusion

Germany
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Advanced BRAFV600 Wild-type Melanoma

United States, Korea, Republic of, Australia, Belgium, France, Russian Federation, Italy, Netherlands, Spain, United Kingdom, Brazil, Poland, Germany, Greece, Hungary
Camurus AB
Novartis

Completed

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Neuroendocrine Tumors | Acromegaly

Germany, Sweden, France, Italy
Idera Pharmaceuticals, Inc.
Bristol-Myers Squibb

Terminated

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Metastatic Melanoma

United States, Canada, Spain, United Kingdom, France, Australia, Germany, Italy, Netherlands, Sweden, Czechia
Eisai Inc.

Completed

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Stage IV Melanoma | Unresectable Stage III

United States, United Kingdom, Australia, Germany
AGO Study Group
Essex Pharma GmbH; MedServ. GmbH, Wiesbaden

Completed

Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

Cervical Cancers | Cancer of the Ovary Treated as 2nd Line Therapy | Muellerian Mixed Tumours | Tumours of the Uterus | Non-Epithelial Ovarian Tumours

Germany
Martin-Luther-Universität Halle-Wittenberg
Merck KGaA, Darmstadt, Germany

Terminated

Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents (HGG-CilMetro)

Gliomas

Germany
European Organisation for Research and Treatment...

Completed

Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma

Glioblastoma

France, Germany, Netherlands, Switzerland, Greece, United States, Austria, Belgium, Italy
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Melanoma | Skin Cancer

United States, Canada, Netherlands, Spain, Australia, Italy, Japan, Germany, Ireland, United Kingdom, Czechia, Switzerland, Poland, France, Greece, New Zealand

Clinical Trials on Neuroectodermal Tumors in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations